Obesity Societies

This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Saxenda® (liraglutide Injection 3 mg) is the first GLP-1 analogue that is EMA and FDA approved for weight management as an adjunct to diet and exercise both in adults and adolescents (12-17 years) with obesity. One pre-filled Saxenda^® pen contains 18 mg liraglutide in 3 ml.¹

The World Obesity Federation

World Obesity Day

The Obesity Society

THE ASSOCIATION FOR THE STUDY OF OBESITY

The Academy for Science and Continuing Education in Diabetes

1.

Saxenda^® Summary of Product Characteristics (Prescribing Information)